Co-Authors
This is a "connection" page, showing publications co-authored by Jordana Cohen and Thomas Hanff.
Connection Strength
1.689
-
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021 03; 9(3):275-284.
Score: 0.231
-
Thrombosis in COVID-19. Am J Hematol. 2020 12; 95(12):1578-1589.
Score: 0.226
-
Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. J Clin Hypertens (Greenwich). 2020 10; 22(10):1780-1788.
Score: 0.226
-
Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations. Clin Infect Dis. 2020 07 28; 71(15):870-874.
Score: 0.224
-
Reply to Tedeschi et al. Clin Infect Dis. 2020 07 28; 71(15):901.
Score: 0.224
-
Relationship Between ACE2 and Other Components of the Renin-Angiotensin System. Curr Hypertens Rep. 2020 06 26; 22(7):44.
Score: 0.222
-
Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19". Circ Res. 2020 06 05; 126(12):e140-e141.
Score: 0.221
-
Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS One. 2021; 16(4):e0248080.
Score: 0.059
-
Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure. Hypertension. 2020 11; 76(5):1526-1536.
Score: 0.057